Moderna, Inc. (NASDAQ:MRNA) Receives $97.18 Average Target Price from Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given a consensus recommendation of “Hold” by the twenty analysts that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $94.65.

A number of research analysts have weighed in on MRNA shares. Sanford C. Bernstein started coverage on Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target on the stock. Leerink Partners reduced their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. HSBC raised Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price target on the stock in a research note on Wednesday, August 28th. Bank of America reduced their price target on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research note on Friday, September 13th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 target price on shares of Moderna in a research report on Thursday, September 19th.

Insider Buying and Selling at Moderna

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total value of $1,799,400.00. Following the transaction, the director now directly owns 2,224,015 shares of the company’s stock, valued at $266,792,839.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total value of $1,799,400.00. Following the transaction, the director now directly owns 2,224,015 shares of the company’s stock, valued at $266,792,839.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,184 shares of company stock valued at $2,037,931 over the last three months. 15.70% of the stock is owned by company insiders.

Institutional Trading of Moderna

A number of hedge funds and other institutional investors have recently modified their holdings of MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna during the second quarter worth about $26,000. Cedar Wealth Management LLC increased its position in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the last quarter. Westside Investment Management Inc. purchased a new stake in shares of Moderna during the first quarter worth about $32,000. Family Firm Inc. purchased a new stake in shares of Moderna during the second quarter worth about $33,000. Finally, Bank & Trust Co purchased a new stake in shares of Moderna during the second quarter worth about $36,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $53.09 on Thursday. The business’s fifty day moving average price is $67.68 and its two-hundred day moving average price is $102.77. The stock has a market cap of $20.41 billion, a PE ratio of -3.45 and a beta of 1.66. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. Moderna has a one year low of $52.26 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the prior year, the firm earned ($3.62) EPS. Moderna’s quarterly revenue was down 29.9% on a year-over-year basis. On average, analysts forecast that Moderna will post -9.94 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.